Eli Lilly and Company
I · Analiza AI
Pe scurt
Eli Lilly discovers, develops, manufactures, and sells prescription medicines globally. Their product portfolio spans diabetes drugs (Humalog, Mounjaro, Trulicity), obesity treatments (Zepbound), cancer therapies (Verzenio, Jaypirca), immunology drugs (Taltz, Olumiant), and Alzheimer's treatments (Kisubla). The company operates manufacturing facilities and research labs, and recently began licensing its AI drug discovery platform (TuneLab) to other biotech firms [Yahoo Finance].
Eli Lilly is a major pharmaceutical company with a $910.8 billion market cap [Yahoo Finance], known for developing drugs for diabetes, obesity, cancer, and immunology. The company is riding a massive wave of growth driven by its obesity and diabetes medications Mounjaro and Zepbound, which now generate roughly $13 billion combined per quarter [GuruFocus]. Recent positive clinical trial data and a $4.50 billion manufacturing expansion [Yahoo Finance] signal the company's commitment to this lucrative market, though this concentration creates significant execution risk.
Eli Lilly is in exceptional financial health, posting explosive growth and strong profitability metrics [Yahoo Finance].
Scor Sentinellis
8.9/10
Financially healthy
Capitalizare bursieră
$910.8B
Venituri (12 luni)
$65.2B
II · Știri recente
Ce a mișcat prețul
6 stories · ranked by relevance
- macro2026-05-20
Eli Lilly Expands TuneLab Access As AI Partnerships Shape R&D Outlook
Simply Wall St
- macro2026-05-20
Engage Bio Acquired by Lilly to Accelerate Development of Non-Viral Genetic Medicines
Yahoo Finance
- macro2026-05-20
Collaborative Drug Discovery Partners with Lilly TuneLab to Make Lilly AI/ML Models Available in CDD Vault
Yahoo Finance
- macro2026-05-20
Bristol Myers to deploy Anthropic's Claude AI model to speed up drug discovery
Yahoo Finance
- macro2026-05-18
Supreme Court Ruling Puts Eli Lilly Medicaid Risks And Dividend In Focus
Simply Wall St
- macro2026-05-19
If You Hold This Healthcare ETF, You’re Losing Big
Yahoo Finance
Premium · gratuit cu orice cont
Extreme revenue concentration: Mounjaro and Zepbound now account for the majority of quarterly revenue at roughly $13 billion combined, meaning any manufacturing issues, safety concerns, or demand slowdown would directly threaten overall financial performance [GuruFocus]
Riscuri
5
Oportunități
5
Semnale de alarmă
3
Conducere
10
Încă 22 de constatări în raportul complet — gratuit cu orice cont.
Deblochează analiza completă Eli Lilly and Company
Fă-ți un cont gratuit ca să vezi raportul complet generat de AI, cu surse citate în text.
- 5 riscuri, 5 oportunități și 3 semnale de alarmă — fiecare cu sursa lui
- Peste 100 de indicatori financiari, cu grafice și comparații
- Rezumate complete ale știrilor, cu linkuri către surse
- Echipa de conducere și remunerația
- Export PDF pentru citit offline
III · Companii similare
Ai putea citi și
Same sector · Healthcare or comparable health
Vrei compania asta pe lista ta?